SC0191 + gemcitabine

SC0191 + gemcitabine is an investigational combination therapy comprised of SC0191, a small molecule inhibitor targeting the serine/threonine-protein kinase WEE1, and gemcitabine, a nucleoside analog antimetabolite chemotherapy. SC0191 inhibits WEE1 kinase, which regulates the G2 DNA damage checkpoint; its inhibition forces cells with damaged DNA (notably TP53-mutant cancer cells) into mitosis, leading to apoptosis[1][3]. Gemcitabine is phosphorylated within cells to form active metabolites that become incorporated into DNA, leading to masked chain termination, DNA fragmentation, and subsequent apoptosis of rapidly dividing malignant cells[2]. The combination is under clinical investigation for advanced cancers, including platinum-resistant or recurrent ovarian cancer, based on the rationale of exploiting synergistic disruption of cell cycle checkpoints and DNA synthesis/repair pathways[3][5].